Expression and clinicopathological significance of Foxp3 and VISTA in cervical cancer.
Foxp3
Treg
VISTA
cervical cancer
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
08
2020
accepted:
27
01
2021
entrez:
15
10
2021
pubmed:
16
10
2021
medline:
16
10
2021
Statut:
epublish
Résumé
To detect the expression differences of Foxp3 and VISTA in chronic cervical inflammation, cervical intraepithelial neoplasia, and cervical cancer, and to explore the role of Foxp3 and VISTA in the development of cervical cancer and the effect of Foxp3 and VISTA on the prognosis of cervical cancer, to provide a theoretical basis for clinical immunotherapy of cervical cancer. We collected 130 paraffin specimens of cervical tissue, which included 70 cases of cervical cancer tissue, 40 cases of cervical intraepithelial neoplasia tissues and 20 cases of chronic cervicitis. The expression of Foxp3 and VISTA in each group was detected, and the study was conducted based on the clinicopathological characteristics of the patients. The patients were followed up and the prognosis was statistically analyzed. 1. The expression of Foxp3 and VISTA was statistically different between the cervical cancer group and other groups. 2. Expressions of Foxp3 and VISTA were significantly correlated. 3. In 70 cases of cervical cancer, the expression of Foxp3 and VISTA was related to the clinical stage. 4. The 3-year survival rate of 70 patients with cervical cancer was 72.9%, and there were no factors affecting 3-year OS found. The expression of Foxp3 and VISTA was significantly correlated with the prognosis of cervical cancer. Foxp3 and VISTA double positive expression group had the worst prognosis. 1. In cervical cancer, the expression of Foxp3 and VISTA was significantly higher than that of cervical intraepithelial neoplasia and chronic cervicitis, which suggested that they were closely related to the occurrence and growth of cervical cancer. 2. The expression of Foxp3 and VISTA was significantly related. 3. The positive expression of Foxp3 and VISTA could be used as independent prognostic factors for cervical cancer prognosis providing a strong basis for cervical cancer immunotherapy.
Types de publication
Journal Article
Langues
eng
Pagination
10428-10438Informations de copyright
AJTR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
J Clin Oncol. 2017 Dec 20;35(36):4035-4041
pubmed: 29095678
J Immunol. 2017 Dec 15;199(12):3943-3951
pubmed: 29093062
Nat Genet. 2001 Jan;27(1):68-73
pubmed: 11138001
Breast Cancer Res Treat. 2011 Jan;125(1):65-72
pubmed: 20229175
BMC Cancer. 2016 Aug 26;16:687
pubmed: 27566250
Rep Pract Oncol Radiother. 2018 Nov-Dec;23(6):580-588
pubmed: 30534022
PLoS One. 2013;8(1):e53630
pubmed: 23382847
Oncoimmunology. 2017 Feb 21;6(4):e1293215
pubmed: 28507801
Cancer Res. 2014 Apr 1;74(7):1933-44
pubmed: 24691994
BJU Int. 2011 Nov;108(10):1672-8
pubmed: 21244603
Sci Rep. 2018 Jun 29;8(1):9847
pubmed: 29959381
Memo. 2016;9:66-69
pubmed: 27429658
Oncoimmunology. 2017 Feb 6;6(3):e1288331
pubmed: 28405521
J Hematol Oncol. 2018 Dec 21;11(1):142
pubmed: 30577797
Cancer Treat Rev. 2018 Jan;62:39-49
pubmed: 29156447
Mol Med Rep. 2018 Apr;17(4):5860-5868
pubmed: 29436663
Immune Netw. 2020 Feb 11;20(1):e4
pubmed: 32158592
Cancer Res. 2014 Apr 1;74(7):1924-32
pubmed: 24691993
Oncotarget. 2017 Dec 7;9(1):641-650
pubmed: 29416641
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Immunology. 2020 May;160(1):24-37
pubmed: 32022254
Nature. 2019 Apr;568(7750):112-116
pubmed: 30918399